BIO - Bio-Rad Laboratories, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
347.11
+3.57 (+1.04%)
As of 10:14AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close343.54
Open344.26
Bid345.95 x 900
Ask347.34 x 1000
Day's Range343.57 - 347.51
52 Week Range220.05 - 348.39
Volume44,075
Avg. Volume218,178
Market Cap10.274B
Beta (3Y Monthly)1.37
PE Ratio (TTM)11.58
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

    Bio-Rad to Report Third-Quarter 2019 Financial Results Thursday, October 31, 2019

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, will report financial results for the third quarter 2019 on Thursday, October 31, 2019, following the close of the market.

  • Business Wire

    Bio-Rad Files New Lawsuit Against 10X Genomics for Patent Infringement

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has filed a patent infringement suit against 10X Genomics, Inc. in the United States District Court for the District of Delaware. In the lawsuit Bio-Rad asserts that 10X Genomics infringes U.S. Patent No. 8,871,444, which is exclusively licensed to Bio-Rad from Harvard University and the Medical Research Council.

  • Business Wire

    Moody’s Upgrades Bio-Rad to Baa2, Reflecting Recent Improvement in the Company’s Operating Performance

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that Moody’s Investors Service (“Moody’s”) upgraded the unsecured rating of Bio-Rad Laboratories, Inc. senior unsecured notes to Baa2 from Baa3. The upgrade also reflects the company’s consistently strong credit metrics. In explaining its rationale for the upgraded credit rating, Moody’s noted that Bio-Rad’s Baa2 rating is supported by the company’s conservative capital structure and strong credit metrics.

  • Business Wire

    Bio-Rad to Participate in Goldman Sachs Annual Global Healthcare Conference on June 11

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, at 10:40 AM , at the Terranea Resort, Rancho Palos Verdes, California.

  • Business Wire

    Bio-Rad to Participate at Jefferies 2019 Global Healthcare Conference on June 4

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, at 10 AM , in New York, NY.

  • Business Wire

    Bio-Rad Reports First Quarter 2019 Financial Results

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2019.

  • Business Wire

    Bio-Rad to Participate in the Bank of America Merrill Lynch Health Care Conference 2019 in May

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 on May 14, at 10:40 AM Pacific Time, at the Encore Hotel, Las Vegas, Nevada.

  • Business Wire

    Bio-Rad Appoints Andrew Last as Executive Vice President and Chief Operating Officer

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dr. Andrew Last as Executive Vice President and Chief Operating Officer, effective April 22, 2019. “We are pleased to have Andrew join Bio-Rad and believe his strong background in global management and leadership spanning the life science, diagnostics, and pharmaceutical industries coupled with his technical expertise will be an invaluable asset to Bio-Rad,” said Norman Schwartz, Bio-Rad President and CEO. Dr. Last brings over 30 years of global management experience to Bio-Rad.

  • Business Wire

    Bio-Rad to Report First-Quarter 2019 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2019 on Wednesday, May 8, 2019, following the close of the market. Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets.

  • Business Wire

    Bio-Rad Receives U.S. FDA Clearance for the IH-500, Expanding Its Offering for the Blood Testing Market

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that it has received 510 clearance from the U.S.

  • Business Wire

    Bio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Ilan Daskal as Executive Vice President and Chief Financial Officer, effective April 6, 2019. Mr. Daskal comes to Bio-Rad from Lumileds, where he served as Chief Financial Officer. Mr. Daskal holds a Masters in Finance degree from City University of New York and a BB in Accounting from Tel-Aviv College of Business in Israel.

  • Business Wire

    Bio-Rad Announces Innovative Test to Aid in the Diagnosis of Lyme Disease with the FDA Clearance of the BioPlex 2200 Lyme Total Assay

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration clearance for its BioPlex 2200 Lyme Total Assay, an innovative multiplex test method to aid in the diagnosis of Lyme disease.

  • GlobeNewswire

    Recent Analysis Shows Transocean, Chipotle Mexican Grill, Marathon Oil, Laboratory Corporation of America, Bio-Rad Laboratories, and Graco Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, March 27, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire

    Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received an expected notice from the New York Stock Exchange (the “NYSE”) stating that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual due to the Company’s delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the "2018 Form 10-K"). As previously disclosed, the reason for the delay is the additional time needed by Bio-Rad to complete its year-end procedures, including its assessment of the effectiveness of the Company’s internal control over financial reporting as of December 31, 2018.

  • PR Newswire

    GBT Reports Fourth Quarter and 2018 Results

    Company Alignment on Long-term Strategic Agenda and Investment on Operation and Execution MONTEVIDEO, Uruguay , March 22, 2019 /PRNewswire/ -- Biotoscana Investments S.A. (B3: GBIO33), a biopharmaceutical ...

  • Business Wire

    Bio-Rad Reports Fourth-Quarter and Full-Year 2018 Financial Results

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2018.

  • Business Wire

    Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S.

  • Business Wire

    Bio-Rad to Report Fourth-Quarter and Full-Year 2018 Financial Results Thursday, February 28, 2019

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2018 on Thursday, February 28, 2019, following the close of the market. To listen, call 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., conference ID: 9099577. Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets.

  • GlobeNewswire

    Report: Developing Opportunities within T-Mobile US, Noble, Akebia Therapeutics, Vornado Realty Trust, Bio-Rad Laboratories, and Standex International — Future Expectations, Projections Moving into 2019

    NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire

    Christine Tsingos Announces Plans to Retire as CFO of Bio-Rad Laboratories, Inc. Effective April 30, 2019

    Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Christine A. Tsingos has informed the company of her intention to retire as Executive Vice President and Chief Financial Officer effective April 30, 2019. Ms. Tsingos will remain in her current role through April 30 and will assist in the orderly transition to a successor. “After 16 years as CFO of Bio-Rad, Christine leaves a tremendous legacy of financial stewardship that has served the company and investors well,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer.

  • Business Wire

    Bio-Rad to Participate at the 37th Annual J.P. Morgan Healthcare Conference on January 8

    Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine Tsingos, Executive Vice President and CFO, will participate in the 37th Annual J.P.